OmniAb (OABI) Gains from Investment Securities (2022 - 2026)
OmniAb (OABI) reported Gains from Investment Securities of -$320000.0 for Q1 2026, down 24.03% year-over-year from -$421224.5 in Q1 2025, and down 28.51% on a QoQ basis from -$249000.0 in Q4 2025.
OmniAb (OABI) has 5 years of Gains from Investment Securities data on file, last reported at -$320000.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 24.03% year-over-year to -$320000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$823000.0 (up 23.87% YoY) and the FY2025 annual result came in at -$761000.0, down 2051.28% from the prior year.
- Gains from Investment Securities retreated to -$320000.0 in Q1 2026 per OABI's latest filing, from -$249000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.9 million in Q3 2024 and bottomed at -$3.4 million in Q2 2024.
- The 5-year median for Gains from Investment Securities is -$93000.0 (2022), against an average of -$78352.9.
- Peak annual rise in Gains from Investment Securities reached 431.06% in 2024, while the deepest fall reached 8537.5% in 2024.
- Tracing OABI's Gains from Investment Securities over 5 years: stood at $1.6 million in 2022, then sank by 114.95% to -$234000.0 in 2023, then surged by 357.69% to $603000.0 in 2024, then plunged by 141.29% to -$249000.0 in 2025, then declined by 28.51% to -$320000.0 in 2026.
- Per Business Quant, the three latest OABI Gains from Investment Securities figures stand at -$320000.0 (Q1 2026), -$249000.0 (Q4 2025), and -$392000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -320,000.00 |
| Mar 31, 2026 | -320,000.00 |
| Dec 31, 2025 | -249,000.00 |
| Dec 31, 2025 | -249,000.00 |
| Sep 30, 2025 | -392,000.00 |
| Sep 30, 2025 | -392,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Mar 31, 2025 | -258,000.00 |
| Mar 31, 2025 | -258,000.00 |
| Dec 31, 2024 | 603,000.00 |
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | -3.38 Mn |
| Jun 30, 2024 | -3.38 Mn |
| Mar 31, 2024 | 862,000.00 |
| Mar 31, 2024 | 862,000.00 |
| Dec 31, 2023 | -234,000.00 |
| Dec 31, 2023 | -234,000.00 |
| Sep 30, 2023 | 367,000.00 |
| Sep 30, 2023 | 367,000.00 |
| Jun 30, 2023 | 40,000.00 |
| Jun 30, 2023 | 40,000.00 |
| Mar 31, 2023 | -273,000.00 |
| Mar 31, 2023 | -273,000.00 |
| Dec 31, 2022 | 1.57 Mn |
| Dec 31, 2022 | 1.57 Mn |
| Sep 30, 2022 | -1.72 Mn |
| Sep 30, 2022 | -1.72 Mn |
| Jun 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 56,000.00 |
| Mar 31, 2022 | -93,000.00 |
| Mar 31, 2022 | -93,000.00 |